Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Company Overview

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies.

Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses. The company is evaluating ACR-368 in selected solid tumors, including ovarian and endometrial cancers, using its OncoSignature approach as a potential biomarker-based companion diagnostic to identify patients most likely to benefit.

The company is also advancing additional targeted oncology programs, including ACR-2316, a selective WEE1 inhibitor. Acrivon was founded in 2018 and is headquartered in Watertown, Massachusetts. Its research and clinical development activities are focused on advancing precision treatments for cancer patients in the United States and other major clinical markets.

Key Stats

• Today's Range: $1.71 to $1.80
• 50-Day Range: $1.70 to $2.39
• 52-Week Range: $1.27 to $3.56
• Volume: 114,455 shs
• Average Volume: 306,773 shs
• Market Capitalization: $75.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Moderate Buy

Acrivon Therapeutics Stock Analysis - MarketRank™

Acrivon Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 486th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Acrivon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Acrivon Therapeutics has a consensus price target of $13.50, representing about 667.0% upside from its current price of $1.76.

Amount of Analyst Coverage

Acrivon Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acrivon Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acrivon Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acrivon Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acrivon Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.22% of the float of Acrivon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Acrivon Therapeutics has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Acrivon Therapeutics has recently increased by 34.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acrivon Therapeutics does not currently pay a dividend.

Dividend Growth

Acrivon Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Acrivon Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Acrivon Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ACRV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,435.00 in company stock.

Percentage Held by Insiders

10.50% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACRV
• CIK: 1781174
• Web: www.acrivon.com
• Phone: 617-207-8979
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acrivon Therapeutics: $13.50
• High Price Target: $19.00
• Low Price Target: $8.00
• Potential Upside/Downside: +667.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.14%
• Return on Assets: -61.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.57 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 42,853,000
• Free Float: 38,353,000
• Market Cap: $75.42 million
• Optionable: Not Optionable
• Beta: 1.91